Signal transduction cascades involved in regulation of the cell cycle machinery are poorly understood. In the Xenopus oocyte model, meiotic maturation is triggered by MPF, a complex of p34 cdc2 -cyclin B, which is activated in response to a progesterone signal by largely unknown mechanisms. We have previously shown that the p21-activated kinase (PAK) family negatively regulates the MPF amplification loop. In this study, we identify the endogenous PAK2 as a key enzyme in this regulation and describe the pathways by which PAK2 is regulated. We show that the small GTPase Cdc42 is required for maintenance of active endogenous X-PAK2 in resting stage VI oocytes, whereas Rac1 is not involved in this regulation. During the process of maturation, X-PAK2 phosphorylation results in its inactivation and allows maturation to proceed to completion. Activation of mitogen-activated protein kinase and cyclin B-p34 cdc2 is coincident with X-PAK2 inactivation, and purified active MPF inhibits X-PAK2, demonstrating the existence of a new positive feedback loop. Our results confirm and extend the importance of p21-activated kinases in the control of the G 2 /M transition. We hypothesize that the X-PAK2/Cdc42 pathway could link p34 cdc2 activity to the major cytoskeleton rearrangements leading to spindle migration and anchorage to the animal pole cortex.
Signal transduction cascades involved in regulation of the cell cycle machinery are poorly understood. In the Xenopus oocyte model, meiotic maturation is triggered by MPF, a complex of p34 cdc2 -cyclin B, which is activated in response to a progesterone signal by largely unknown mechanisms. We have previously shown that the p21-activated kinase (PAK) family negatively regulates the MPF amplification loop. In this study, we identify the endogenous PAK2 as a key enzyme in this regulation and describe the pathways by which PAK2 is regulated. We show that the small GTPase Cdc42 is required for maintenance of active endogenous X-PAK2 in resting stage VI oocytes, whereas Rac1 is not involved in this regulation. During the process of maturation, X-PAK2 phosphorylation results in its inactivation and allows maturation to proceed to completion. Activation of mitogen-activated protein kinase and cyclin B-p34 cdc2 is coincident with X-PAK2 inactivation, and purified active MPF inhibits X-PAK2, demonstrating the existence of a new positive feedback loop. Our results confirm and extend the importance of p21-activated kinases in the control of the G 2 /M transition. We hypothesize that the X-PAK2/Cdc42 pathway could link p34 cdc2 activity to the major cytoskeleton rearrangements leading to spindle migration and anchorage to the animal pole cortex.
During oocyte maturation, the G 2 /M transition is highly regulated. In Xenopus, it is widely accepted that the steroid hormone progesterone is the trigger required to turn on the signal transduction pathway leading to maturation. Events that occur during this transition, including the synthesis of the protooncogene product c-Mos and the activation of both MAP 1 kinase and cyclin B-cdc2 (MPF), have been thoroughly documented (1) (2) (3) (4) . Nevertheless, a complete understanding of the many pathways involved is not yet a reality. The identification of several new players is therefore of great importance in piecing together the maturation puzzle. The serine-threonine kinase Eg2 has been reported to be phosphorylated soon after progesterone stimulation. Overexpression in oocytes of the Eg2 kinase stimulates new c-Mos protein synthesis and facilitates entry into metaphase II (5) . Positioning of Eg2 in regard to the translational activation of c-Mos mRNA should lead to a better picture of early events occurring after oocyte stimulation by progesterone. Another serine-threonine kinase, glycogen synthase kinase-3␤, has been shown to be inactivated in response to progesterone and overproduction of wild type glycogen synthase kinase-3␤ specifically blocked oocyte maturation (6) . Speedy, another interesting protein with no apparent enzymatic activity, was also identified to activate MAP kinase and induce G 2 /M transition by a novel pathway that appears to be completely independent of c-Mos (7) .
We have reported the involvement of the p21-activated kinase family (PAK) in the regulation of the G 2 /M transition by the demonstration that a truncated catalytically active form of X-PAK1 blocks progesterone-induced oocyte maturation, whereas a dominant negative form facilitates the process. More specifically, we showed that PAKs act by preventing the MPF amplification loop from being turned on. Indeed, when X-PAK1 kinase activity is present in progesterone-treated oocytes, we observed that the p34 cdc2 negative regulatory kinases Wee1/ Myt1 are kept active, whereas the Cdc25 activating phosphatase is not activated (8, 9) . PAKs are serine/threonine kinases, of which the prototype Ste20 was first identified in Saccharomyces cerevisiae as an upstream regulator of the MAP kinase cascade that is turned on during mating (10, 11) . Ste20 is activated by binding the GTP-bound form of Cdc42 (12) . Since this pioneering work, PAKs have emerged as a major kinase family, to which numerous functions have been assigned in the control of MAP kinase cascades and in cytoskeleton rearrangements (13) (14) (15) (16) (17) .
Progesterone-induced oocyte maturation involves major morphological changes in the oocyte as the microtubule array moves with the nucleus toward the animal pole and the meiosis I spindle is attached to the cortex through the actin cytoskeleton (18, 19) , which is then completely remodeled. However, few studies have been undertaken to establish a link between these extensive and obligatory morphological changes and MPF activation.
In S. cerevisiae, a recent report has demonstrated a direct link between cortical cytoskeleton rearrangement and activation of the mitotic cyclin-Cdk complex Clb2-CDC28. This elegant piece of work demonstrate a coupling between septin function and the activation of Hsl1, a Nim1-related kinase previously identified as a negative regulator of Swe1 (a Wee-1 homolog in S. cerevisiae) during isotopic bud growth (20) . Interestingly, Tjandra et al. (21) showed that Gin4, another Nim1-related kinase, is also involved in control of specific mitotic Clb2-dependent events in S. cerevisiae, jointly with other partners, including both the GTPase Cdc42 and Cla4, a PAK homolog. Cdc42, which belongs to the family of Rho GTPases (for review, see Ref. 22) , controls the organization of actin filaments in the cell in higher eukaryotes and is directly involved in modulation of cell shape, as well as in the migration/ adhesion properties of the cells, and in the formation of the cleavage furrow when the cell divides (23) (24) (25) (26) .
In this report, we show that the GDP-bound form of the small GTPase Cdc42 greatly facilitates progesterone-induced maturation, whereas its GTP-bound form completely blocks the process. Interestingly, Rac1-GTP has no effect on this complex pathway. Cdc42 acts in the control of the maturation pathway, at least partly through a Xenopus PAK that we have identified as X-PAK2, an as yet unreported PAK member in Xenopus with an almost total identity with human PAK2. We further show that endogenous X-PAK2 activity is indeed negatively regulated during maturation. Inactivation of X-PAK2 occurs late in progesterone signaling and is coincident with the appearance of H1 kinase activity. Finally, we demonstrate that X-PAK2 is inactivated by phosphorylation, which is mediated by the newly activated cyclin B-p34 cdc2 kinase.
EXPERIMENTAL PROCEDURES

cDNA Cloning
The X-PAK2 kinase domain was amplified from cDNAs prepared from metaphase II-arrested eggs and further used to screen a gt10 library as described previously (8) . As in all the positive clones isolated the initiation codon was lacking, specific primers were designed according to the Marathon 5Ј-rapid amplification of cDNA ends protocol (CLONTECH) and the 5Ј-end of X-PAK2 cDNA was cloned (according to the manufacturer's instructions). A complete full-length clone was reconstructed using classical molecular biology techniques.
Xenopus Oocytes Microinjection and Egg Extracts
Xenopus females were obtained from the CNRS breeding center located in Montpellier, France. Fully grown oocytes were prepared, free from follicle cells, by collagenase treatment in Ca 2ϩ -free OR 2 (27) and then transferred to MMR (100 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 2 mM CaCl 2 , 0.1 mM EGTA, 5 mM HEPES, pH 7.7), in which all experiments were performed. The usual volume microinjected was 40 nl; injections were performed near the equator of the oocytes. Progesterone was used at a final concentration of 30 M.
Oocytes were homogenized (10 l per oocyte) in XB buffer (50 mM sucrose, 100 mM KCl, 0.1 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, pH 7.8) and then briefly centrifuged for 2 min at 20,000 ϫ g to remove yolk proteins. Supernatants were then used for Western blots, immunoprecipitations, or in-gel kinase assays.
Cytostatic factor activity (CSF)-arrested egg extracts were prepared as described previously (28) . Briefly, fresh eggs were dejellied in 2% cysteine (pH 7.8) and washed in XB buffer in the presence of EGTA (6 mM). Eggs were crushed at 20,000 ϫ g for 15 min, and the cytoplasmic layer was supplemented with an ATP regenerating system, cytochalasin B, and protease inhibitors, before use.
MPF Purification
Cyclin B-p34cdc2 kinase was prepared from starfish oocytes by affinity chromatography on p13suc1-Sepharose, ion exchange chromatography, and monoS columns as described previously (29) .
Purification of Recombinant Proteins
X-PAK2-MalBP Constructs-Oligonucleotides X-PAK2N5Ј (ggccggatcctctgataacggggagcttg) and X-PAK2N3Ј (gcccgtcgactcatcactgtctgtctccagtctt) were used to amplify the N-terminal domain of X-PAK2, and X-PAK2C5Ј (ggccggatccgaaaaacttagaactatag) and X-PAK2C3Ј(gcccgtcgactcatcagcggtttcccttcattgc) were used to amplify the C-terminal domain. Polymerase chain reaction products were subcloned into pMal-P2 (New England Biolabs) prokaryotic expression vector.
Recombinant MalBP-X-PAK fusion proteins were expressed in E. coli and purified according to the manufacturer's instructions (New England Biolabs). Fusion proteins were further used for oocyte microinjection and, for the MBP-X-PAK2 Nter, to raise antibodies in rabbits.
Cdc42-and Rac-GST Fusion Proteins-All Cdc42 and Rac point mutants (a kind gift of Dr. A. Hall), were expressed in E. coli from the pGEX prokaryotic expression vector as recombinant glutathione Stransferase fusion proteins and were purified on glutathione-agarose beads essentially as described by the manufacturer (Amersham Pharmacia Biotech).
The sea urchin GST-cyclin B construct was kindly donated by Dr J. Gautier (GST is fused to sea urchin type B cyclin from amino acid 13 to 409), and the recombinant protein was expressed in E. coli and affinity purified as described previously (9) .
Kinase Assays
Histone H1 kinase activities were assayed according to the protocol described (29) . Briefly, cyclin B-p34 cdc2 complexes immunoprecipitated with antibodies directed against the C-terminal peptide of p34 cdc2 were incubated for 15 min in 20 l of kinase buffer (8) containing 1 l of histone H1 at 5 mg/ml, 1 l of 1 mM ATP, and 0.5 l of [␥-
32 P]ATP (3000Ci/mmol) to reach a final [␥-
32 P]ATP specific activity of 4.5 Ci/ mmol). Immunoprecipitates were subjected to 15% SDS-polyacrylamide gel electrophoresis and visualized by autoradiography. X-PAK2 activity was tested from extracts immunoprecipitated with X-PAK2-Nter antibodies, using H2B as a substrate, in the same conditions as for the H1 assays.
In-gel MBP kinase assays were performed essentially as described previously (30) . Briefly, samples were run in a 15% polyacrylamide gels containing 0.5 mg/ml MBP. After denaturation and renaturation steps, gels were incubated in the presence of [␥-
32 P]ATP. Gels were washed and dried; in-gel MBP kinases were visualized by autoradiography.
Phosphatase Assays
-Phosphatase from New England Biolabs was added to the extracts at 8000 units/per ml in a final reaction volume of 50 l, reactions were carried out for 30 min at 30°C, and 2-l aliquots were used in Western blot assays.
Roscovitin Assays
Ten microliters of CSF-arrested extracts were treated with increasing quantities of Roscovitin fused with MalBP for 90 min at room temperature. Two microliters of the reactions were further used for Western blot, and for H1 kinase assay of p34 cdc2 immunoprecipitates.
Immunoprecipitations and Western Blots
Monoclonal antibodies directed against the active tyrosine-phosphorylated form of MAP kinase was obtained from Santa Cruz, USA (catalog no. sc7383). Polyclonal antibodies prepared against the C-terminal peptide of Xenopus p34 cdc2 were prepared in the laboratory. Xenopus X-PAK2 and Xenopus X-PAK1 polyclonal antibodies were made in the laboratory by immunizing rabbits against the recombinant N-terminal domain of X-PAK2 (amino acids 2-214) or X-PAK1 (amino acids 2-222) fused with MBP.
All immunoprecipitates were performed by incubation of the extracts with the indicated antibodies linked to protein A-Sepharose in modified RIPA buffer for 1 h at 4°C and washed three times in modified RIPA buffer and twice in kinase buffer (25 mM HEPES, pH 7.5, 25 mM MgCl 2 , 25 mM ␤-glycerophosphate, 2 mM dithiothreitol, and 0.1 mM orthovanadate).
X-PAK1 and X-PAK2 Western blots and immunoprecipitates were performed with antibodies immunopurified against the corresponding recombinant proteins.
RESULTS
Cdc42 but Not Rac1 Is Involved in Control of the G 2 /M Progression during Xenopus
Oocyte Maturation-In order to assess a potential role of the Rho family GTPases in oocyte maturation, we microinjected exogenous, constitutively GTPor GDP-bound forms of Cdc42 and Rac1 (Val-12 and Asn-17 point mutants, respectively) 1 h before progesterone treatment and scored the germinal vesicle breakdown, according to the appearance of a white spot on the animal pole (31) . As shown in Fig. 1A , in control progesterone-treated oocytes, 50% germinal vesicle breakdown (GVBD) was attained by 4 h of hormonal treatment. Microinjection of equal amounts of either RacN17 or RacV12 did not affect the kinetics of oocyte maturation by progesterone. In contrast, a complete inhibition of progesterone-induced maturation was observed in the presence of the Cdc42V12 mutant. Consistent with this observation, the Cdc42N17 mutant facilitated the oocyte response to hormone treatment, as GVBD 50 occurred reproducibly under these con-ditions between 1 and 2 h earlier than was observed with progesterone alone. The occurrence of GVBD was corroborated by both the measure of H1 kinase activity of p34 cdc2 immunoprecipitates and by the activation of MAP kinase in an in-gel kinase assay using myelin basic protein (MBP) as a substrate (Fig. 1B) . As expected, a strong H1 kinase activity was associated with the immunoprecipitates of p34 cdc2 kinase from oocytes extracts prepared 7 h after progesterone treatment. This level of H1 kinase activity was not modified by microinjection of either GDP-or GTP-bound form of the Rac1 GTPase, whereas H1 kinase activity peaked 1-2 h earlier in the Cdc42N17-microinjected oocytes (data not shown). In contrast, microinjection of the Cdc42V12 mutant prevented H1 kinase activation (Fig. 1B) . In all of the conditions described above, H1 kinase activation systematically correlated with MAP kinase activation, and as expected, only control oocytes (stage VI) and Cdc42V12-microinjected oocytes lack MAP kinase activity (Fig. 1B) .
Our results thus indicate that Cdc42 but not Rac1 is involved in the control of maturation, as inactivation of the signaling pathway downstream from Cdc42 facilitates oocyte response to the hormone. In order to more clearly define through which effector Cdc42V12 prevents the maturation process, we took advantage of two point mutants that have been previously shown to specifically disrupt the binding of different effectors (32) . Cdc42L61 is, like Cdc42V12, in a GTP-bound form. The Cdc42L61A37 double mutant can still bind p65PAK, p50RhoGAP, and WASP effectors, whereas Cdc42L61C40 still binds p50RhoGAP but is unable to bind p65PAK (33) . Expression of the Cdc42L61C40 mutant in progesterone-treated oocytes (Fig. 1A ) resulted, as with the GDP-bound Cdc42N17 mutant, in facilitation of the G 2 /M transition. Both mutants, although for different reasons, are unable to activate the PAK/ WASP pathway, which suggests that silencing the endogenous PAK and/or WASP pathway results in premature activation of MPF and more rapid onset of GVBD. Such a mechanism indeed supports our previous results on the induction of a maturation block by active X-PAK (8 -9) . In contrast, expression of the Cdc42L61A37 mutant did not affect progesterone-induced oocyte maturation. These results led us to analyze the state of activation, in the oocyte, of the endogenous PAKs, upon expression of the well characterized Cdc42 point mutants.
X-PAK2 Is the Target of Cdc42 in the Control of Progesteroneinduced Maturation-
We looked to see whether a correlation could be made between the ability of Cdc42 GTPase mutants to bind and activate PAK effectors and their effect on the maturation pathway. Because the third Xenopus PAK homolog that we isolated is poorly conserved among the PAK family, we did not examine this kinase further and only tested X-PAK1 and X-PAK2 activation.
We first analyzed the endogenous X-PAK2 ( Fig. 2A ) and X-PAK1 (Fig. 2B ) activities present in stage VI oocytes and mature eggs (Pg) (Fig. 2, A and B, left panels) . In stage VI oocytes, X-PAK2 activity is at least a factor of 20 above that associated with X-PAK-1. In mature oocytes, endogenous X-PAK2 activity decreased significantly, whereas X-PAK1 associated kinase activity appeared to remain unchanged, and this was indeed confirmed upon longer exposure of the autoradiogram (data not shown). As we previously reported that X-PAK1 is capable of using histone H2B as a substrate (9), we conclude that endogenous X-PAK2 but not X-PAK1 activity is downregulated during the maturation process.
Next, GTP-bound (V12, L61A37, and L61C40) or GDP-bound (N17) forms of Cdc42 were microinjected into oocytes prior to treatment with progesterone. Oocytes were withdrawn at different times after hormone addition and endogenous X-PAK1 and X-PAK2 kinase activities tested.
Injection of GDP-bound Cdc42 (N17 mutant) did not change endogenous X-PAK activities. In contrast, upon Cdc42V12 microinjection, X-PAK2 associated H2 kinase activity increased 5-10-fold, as soon as 30 min after GTPase microinjection ( Fig.  2A) . This was also true to some degree for activation of X-PAK1 (Fig. 2B) , although the H2B associated kinase activity barely reached the basal activity associated with X-PAK2. As both X-PAK1 and X-PAK2 can bind and be activated as efficiently by GTP-bound Cdc42 in vitro (8), 2 we thus hypothesize
FIG. 1. Oocyte maturation upon GTPase microinjection.
A, time course of GVBD of control untreated, progesterone-treated, or GTPase-injected oocytes prior to progesterone stimulation (10 g/ml). Purified point-mutated recombinant GTPases in fusion with GST were injected at a final concentration of 10 g/ml, 1 h before progesterone treatment, and GVBD was scored as a function of time. RacV12 (broken line and filled triangles), RacN17 (broken line and filled squares), and Cdc42L61A37 (open triangles) time courses of maturation were similar to control progesterone-treated oocytes (filled circles). Cdc42V12 (filled triangles)-microinjected oocytes failed to undergo GVBD. Both Cdc42N17 (filled squares) and Cdc42L61C40 (open squares) reproducibly facilitated oocyte maturation, and facilitation of maturation at 50% GVBD is indicated. This experiment was repeated with similar results four times. We verified that GST microinjection did not affect oocyte maturation time course. B, control and GTPase-microinjected oocytes treated (ϩ) or not treated (Ϫ) with progesterone were harvested 7 h after hormonal treatment, homogenized, and briefly centrifuged, and supernatants were further used. An aliquot (2 oocyte equivalents) was used to measure MAP kinase activity by in-gel phosphorylation of MBP substrate (top panel), and a second aliquot was used to measure H1 kinase activities on p34 cdc2 immunoprecipitates (bottom panel). MAP kinase and MPF activations were consistent in all cases. No maturation was ever observed with mutant GTPase in absence of hormonal treatment (Ϫ). The Cdc42V12 point mutant completely blocked progesterone-induced maturation, and no MPF or MAP kinase activation could be detected.
that either X-PAK1 localization or conformation prevents its proper interaction with Cdc42 in stage VI oocytes. These results indicate that Cdc42V12 probably prevents hormone-induced oocyte maturation by acting through its endogenous X-PAK2 effector. Indeed recombinant active X-PAK2 blocks the maturation process (data not shown). This is further confirmed by the expression of the Cdc42L61C40 mutant in progesteronetreated oocytes ( Fig. 2A) . Cdc42L61C40 is unable to activate X-PAK2 ( Fig. 2A) and also facilitates progesterone-induced oocyte maturation in a similar manner to the Cdc42N17 mutant (Fig. 1) . In contrast, a strong activation of X-PAK2 does occur in the presence of the Cdc42L61A37 mutant but is considerably delayed (Fig. 2A , compare Cdc42 V12 and Cdc42L61A37). It was reported previously that the Cdc42L61A37 mutant is capable of binding and activating p65PAK as well as did the nonmutated versions (33) . This is, however, clearly not the case for Xenopus PAK2. X-PAK2 activation could be delayed because we use a heterologous recombinant GTPase, which could potentially have different binding properties from the endogenous Xenopus Cdc42 partner of X-PAK2. Nevertheless, Cdc42L61A37 does not interfere with the maturation process. This result raises two possibilities: either X-PAK2 is not the true Cdc42 effector in the G 2 /M block, or its activation by Cdc42L61A37 occurs too late in the maturation process to interfere with it. To discriminate between these two hypotheses, we microinjected Cdc42L61A37 mutants in oocytes 3 h before further treatment with progesterone. Under these conditions, GVBD did not occur, and maturation was blocked (data not shown). Altogether, these results show that the Cdc42/X-PAK2 pathway negatively regulates hormone-induced oocyte maturation and that the maturation block can be bypassed if the Cdc42/X-PAK2 pathway is activated after 50% GVBD.
X-PAK2 Activity Is Regulated during Oocyte Maturation and Fertilization-A full-length X-PAK2 clone was obtained by a combination of library screening and 5Ј-rapid amplification of cDNA ends polymerase chain reaction; the cDNA sequence information is available in GenBank TM (accession number AJ242726). X-PAK2 is likely to be the true homologue of human PAK2, as both kinases share an overall identity of 87.5%. Fig. 3 shows the amino acid sequence comparison of both kinases. The Src homology 3 binding domains and the Cdc42 and Rac interactive binding (CRIB) sequence are closely related, and their kinase domains are almost identical. We analyzed X-PAK2 expression and activity during the course of maturation (Fig. 4A) . Progesterone-treated oocytes were harvested every 30 min, and oocyte extracts were subsequently used to correlate X-PAK2 mobility (in Western blot, Fig. 4B ) with its activity on immunoprecipitates against H2B as a substrate (Fig. 4D ) and with both MAP kinase activity (Fig. 4C ) and cyclin B-p34cdc2 kinase activity (Fig. 4E) .
X-PAK2 mobility decreases during the course of maturation at 3.5 h after progesterone treatment, and a subpopulation of X-PAK2 is shifted to a slower mobility form (Fig. 4B) . The X-PAK2 kinase assay reveals that the fastest species present in oocytes, at the beginning of the maturation time course, is active X-PAK2 (Fig. 4D) . The ratio between the two bands can vary between different batches of eggs, but the appearance of the upper band late in the maturation process is always correlated with a loss of endogenous X-PAK2 activity (compare Fig.  4 , B and D, at 3 and 3.5 h). Down-regulation of X-PAK2 is not an early event during the process of maturation, as it appears to be coincident with the activation of both cyclin B-p34cdc2 complexes (Fig. 4E ) and MAP kinase (Fig. 4C) , slightly before 50% GVBD (Fig. 4A) . X-PAK2 inactivation is not restricted to progesterone mediated maturation. Indeed, when maturation was induced by either recombinant cyclin B or insulin treatment, a decrease in X-PAK2 mobility was also observed and again correlated with X-PAK2 inactivation (data not shown).
Laid eggs are arrested in metaphase of second meiosis, with high MPF and CSF (in which the proto-oncogene encoding c-Mos participates) activities (4), whereas upon fertilization, both cyclin B and c-Mos are degraded and the embryo enters the first embryonic cell cycle. We treated laid eggs with the calcium ionophore A23187, which induces a calcium release and cyclin degradation and mimics fertilization. X-PAK2 mobility in Western blot increases upon 2 min of ionophore treatment, and loss of the slower mobility specie was again correlated by the activation of the kinase as in stage VI oocytes (data not shown).
In conclusion, X-PAK2 is inactivated during maturation upon MPF and MAP kinase activation and reactivated upon fertilization. Loss of activity is correlated by the appearance of a subpopulation with reduced electrophoretic mobility. We therefore asked whether X-PAK2 inactivation during maturation is due to phosphorylation.
X-PAK2 Activity Is Down-regulated by Phosphorylation-A number of autophosphorylation sites have been mapped for p21-activated kinases (16) , and additional and activating sites are autophosphorylated upon binding of Cdc42 guanosine 5Ј-3-O-(thio)triphosphate, which results in the appearance of more acidic forms on two-dimensional gels (34) .
To see whether X-PAK2 is phosphorylated during maturation, we compared endogenous X-PAK2 patterns from stage 6 oocytes and CSF-arrested eggs resolved by two-dimensional gel
FIG. 2. Time course of X-PAK1 and X-PAK2 activations in GTPases microinjected and progesterone-treated oocytes.
Stage VI oocytes were microinjected with purified point-mutated recombinant GTPases in fusion with GST at a final concentration of 10 g/ml, 1 h before progesterone treatment. Controls were untreated stage VI oocytes (StVI) and oocytes treated with progesterone for 7 h (Pg). At the indicated times (0.5, 2, 4, and 6 h), oocytes were withdrawn, homogenized, and briefly centrifuged, and supernatants were further used. X-PAK2 (A) and X-PAK1 (B) endogenous kinases were recovered on their specific immunopurified antibodies (directed against the N-terminal domain of the kinases) linked to protein A-Sepharose, and their specific activities were tested in kinase assays against H2B as a substrate. Panel A indicates that X-PAK2 is active in resting stage VI oocytes (StVI) and inactive in mature (Pg) eggs. Neither Cdc42N17 nor Cdc42L61C40 is capable of activating endogenous X-PAK2. In contrast, X-PAK2 activity was increased at least 10-fold by 30 min and peaked at 2 h, when oocytes were microinjected with Cdc42V12. Cdc42L61A37 is capable of activating endogenous X-PAK2, but activation occurred only after 4 h of progesterone treatment, when GVBD 50 was already reached. Panel B shows that X-PAK1 activity is comparable in resting and mature oocytes (even upon longer exposure). Microinjection of the various mutated GTPases did not induce any significant X-PAK1 activation.
electrophoresis and revealed by Western blot. Endogenous X-PAK2 exists in both oocytes and eggs in different forms, resolved as multiple species in the first electrofocusing dimension. Nine major species, with isoelectric points (pI) in the range of 5.4 -6.4, were detected in stage VI oocytes, whereas a general shift toward more acidic forms and the strong enrichment in two additional species (also shifted in SDS-polyacrylamide gel electrophoresis) with respective pI values of 5 and 5.2 were detected following maturation (data not shown). The fact that both CSF-specific species are more acidic could be the result of additional regulatory phosphorylation of the protein.
In order to verify whether X-PAK2 is down-regulated by phosphorylation, stage VI oocytes and mature CSF-arrested egg extracts were prepared, and aliquots were treated either with phosphatase or with buffer alone and analyzed by Western blot (Fig. 5) . The X-PAK2 lower mobility species, observed in the CSF extract, is indeed sensitive to phosphatase treatment, as a single species is detected that comigrates with the active form present in untreated oocytes. We conclude that X-PAK2 is down-regulated by phosphorylation during maturation.
X-PAK2 Activity Is Down-regulated by MPF Activity-Inactivation of X-PAK2 is coincident with H1 kinase activation (see Fig. 4, D and E) , an obligatory step in progesterone-induced maturation. We have reported previously (9) that microinjection of active X-PAK1 blocks the maturation process by preventing the amplification loop of MPF from being turned on. These data led us to consider whether MPF could be responsible for the inactivation of endogenous X-PAK2 during hormoneinduced oocyte maturation.
To address this question, we treated CSF-arrested egg extract with increasing concentrations of Roscovitin (a specific inhibitor of MAP kinase, cyclin B-p34 cdc2 , cyclin A/E-p34 cdk2 kinase, and p35-Cdk5 kinase (35) ) to compare the inactivation profiles of MPF and MAP kinase, the two major active kinases present in the mitotic arrested extracts, with the activity of endogenous X-PAK2 kinase. After 90 min of treatment, extracts were tested for MPF activity on p34 cdc2 immunoprecipitates (Fig. 6A) , for MAP kinase activity by MBP phosphorylation in an in-gel kinase assay (Fig. 6B) , and for X-PAK2 activity by their mobility on Western blot (Fig. 6C) . Control kinase activities are stage VI oocytes and buffer-treated CSF-arrested egg extract (0 M Roscovitin); cyclin B-p34 cdc2 is inactivated between 10 and 15 M Roscovitin (Fig. 6A) , whereas, unlike previous reports, MAP kinase is inactivated at slightly lower concentrations (Fig. 6B) . X-PAK2 increased mobility (Fig. 6C ) strictly correlates with its activation (data not shown) and with H1 kinase inactivation (Fig. 6A) .
Thus, MPF but not MAP kinase may be the kinase involved in the down-regulation of X-PAK2. This result is in agreement with the timing of the early reactivation of X-PAK2 kinase, which we observed upon fertilization. Indeed, cyclin B degra- 
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dation and MPF inactivation occur soon after fertilization, whereas MAP kinase is inactivated 30 min later (36) . To confirm this result, increasing amounts of active purified starfish MPF (29) were added to X-PAK2, immunoprecipitated from oocyte extracts, for 30 min in the presence of ATP, before addition for another 15 min of [␥-32 P]ATP and both histone H1 and histone H2B. Kinase assays subjected to SDS-polyacrylamide gel electrophoresis were autoradiographed (Fig. 7) . Endogenous control X-PAK2 used exclusively histone H2B as a substrate (Fig. 7, left lane) , as no histone H1 was labeled. Control MPF kinase added in the experiment (second lane from left) used only H1 as a substrate, as no H2B labeling occurred during the kinase assays. Purified MPF activity equivalent to H1 kinase activity present in 2.5, 5, and 10 CSF-arrested eggs was added to 4 oocyte equivalents of preimmune or X-PAK2
immunoprecipitates. As expected, no H2 kinase activity was retained on the preimmune precipitates, and H1 kinase activity appeared stable, even though an increasing quantity of MPF was added (Fig. 7 , compare H1 activity in lanes 2.5, 5, and 10) because histone H1 substrate was added at a limiting concentration, for the clarity of interpretation of the autoradiogram. A faint labeled band of 50 kDa is likely to represent the phosphorylation of the MPF cyclin B subunit, which is a poor substrate compared with H1. In contrast, incubation of X-PAK2-specific immunoprecipitates with increasing quantities of MPF results in a complete inactivation of X-PAK2 kinase, assayed against histone H2B. Thus, these results present evidence of down-regulation of a member of the p21-activated In this experiment, GVBD 50 occurred 4 h after progesterone treatment. During the course of the experiment, oocytes were withdrawn every 30 min, homogenized, and briefly centrifuged, and supernatants were further used. X-PAK2 mobility and accumulation were monitored by Western blotting using anti-X-PAK2 immunopurified antibodies (B); MAP kinase activation was monitored by Western blotting using antibodies that specifically recognize the active tyrosinephosphorylated form (circled P) of MAP kinase (C); X-PAK2 activity was tested on purified X-PAK2 immunoprecipitates using H2B as a substrate (D). Cyclin B-p34 cdc2 activation was tested on purified p34 cdc2 immunoprecipitates against H1 as a substrate (E). X-PAK2 was active up to 3 h after hormonal treatment (C), and its accumulation did not change (B), whereas neither H1 (E) nor MAP kinase (C) activity was detected. Around GVBD 50 , X-PAK2 was inactivated (D), and a new X-PAK2 species with a slower mobility was detected by Western blot (B). Coincident with these events, both MAP kinase (C) and MPF (E) activations occurred.
FIG. 5. X-PAK2 is phosphorylated during oocyte maturation. Extracts were prepared from untreated (StVI) or mature (Pg) oocytes treated for 7 h with progesterone, and the latter was then subjected to -phosphatase treatment (PPase, ϩ) for 30 min. Western blots were performed using purified X-PAK2 antibodies. The X-PAK2-shifted species was present in progesterone-treated oocytes and disappeared upon treatment of the extract with -phosphatase, demonstrating that X-PAK2 is phosphorylated during oocyte maturation.
FIG. 6. X-PAK2 reactivation is coincident with MPF inactivation by Roscovitin. CSF-arrested egg extracts were treated with increasing concentration (as indicated) of Roscovitin (CalBiochem) for 90 min at room temperature, and aliquots were withdrawn and analyzed for H1 kinase activity on p34cdc2 immunoprecipitates (A), for MAP kinase activity on Western blot using antibodies directed against the active tyrosine-phosphorylated form of MAP kinase (Santa-Cruz) (B), and for X-PAK2 activity on Western blot as tested by its electrophoretic mobility using specific anti X-PAK2 antibodies (C). Roscovitin induces the inactivation of MPF associated H1 kinase activity at around 15 M. The inactivation of H1 is correlated with the appearance of the fastest (active) migrating species of X-PAK2, indicating that X-PAK2 is reactivated upon MPF inactivation. MAP kinase is inactivated under these conditions at lower doses of Roscovitin (between 5 and 10 M). Controls are extracts prepared from stage VI oocytes (StVI) and untreated CSF extract (0 M Roscovitin).
FIG. 7.
Active immunoprecipitated X-PAK2 is inactivated by purified MPF. Increasing amounts of purified MPF (H1 kinase activity derived from 2.5, 5, and 10 CSF-arrested eggs) were added, in the presence of 1 mM ATP and for 30 min, to preimmune or X-PAK2-specific immunoprecipitates (X-PAK2 IP) prepared from four stage VI oocytes, in which endogenous X-PAK2 is active, before further addition of histone H1 as a substrate for MPF and histone H2B as a substrate for endogenous X-PAK2 and cold (50 M) and labeled (0.5 l) ATP, for another 15 min. Identical kinase assays were performed with controls prepared from X-PAK2 immunoprecipitated from stage VI oocytes but not untreated with MPF (left lane) and purified MPF alone (second lane from left). X-PAK2 kinase activity tested against H2B was specifically inactivated when MPF is added at the highest concentration. Thus, in this particular experiment, an H1 kinase activity (associated to cyclin B-p34 cdc2 ), developed in 10 CSF-arrested eggs, is required to inactivate the H2 kinase activity associated with X-PAK2 present in four stage VI oocytes.
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kinase, by phosphorylation by an active cyclin-Cdk complex, during oocyte maturation.
DISCUSSION
Xenopus PAK2 and Cdc42 GTPase in the Control of the Maturation Process-In this study
, we wished to analyze the pathway to which PAK belongs in the control of progesteroneinduced maturation. We demonstrate that Rac1 GTPase has no effect on the G 2 /M transition during oocyte maturation, whereas under the same conditions, GTP-bound Cdc42 prevents oocyte maturation. We took advantage of the well described point mutations in GTPases that prevent binding of some of their effectors (33) to pinpoint the target of Cdc42 to either WASP or a PAK. As microinjection of WASP did not significantly affect progesterone-mediated oocyte maturation, and because we reported previously that the recombinant active kinase domain of X-PAK1 (X-PAK1-Cter) induces a G 2 /M transition block (8 -9), we more closely studied the activation of Xenopus PAK by Cdc42. Because PAK kinase domains are extremely well conserved (85% of identity between X-PAK1 and X-PAK2 kinase domains), when using X-PAK1-Cter, we were aware that our results did not necessarily imply that X-PAK1 is the physiological kinase involved in the block of the G 2 /M transition. Indeed, we show in this study that X-PAK2, not X-PAK1, is the likely target of a Cdc42 GTPase in negative control of maturation. X-PAK2 is the preferred PAK effector of GTP-bound Cdc42 (Cdc42V12 mutant) in resting stage VI oocytes, because microinjection of Cdc42V12 increases its basal activity by up to 50-fold, which results in a complete block in maturation (we verified that the same amount of activity of a recombinant active X-PAK2 is also capable of blocking the G 2 /M transition during progesterone-induced maturation, data not shown). In contrast, endogenous X-PAK1 is only poorly activated under the same conditions. Moreover, we found that endogenous X-PAK2 is regulated during early development. X-PAK2 is active in stage VI oocytes (although not to a level that blocks the occurrence of G 2 /M transition under hormonal stimulation) and then inactivated in M phase and reactivated at the exit of meiosis upon cyclin degradation.
Another point we previously made using recombinant X-PAK1-Cter (8) was that GTPases were unlikely to be involved in the G 2 /M transition for two reasons. The first is that microinjection of the N-terminal regulatory domain (X-PAK1-Nter) does not interfere with progesterone-induced maturation, and the second is that the kinase dead domain (X-PAK1-Cter K/R) acts as a dominant negative mutant by greatly facilitating progesterone-induced maturation. In light of the results we describe in this report, we propose that X-PAK1-Nter has no effect on the G 2 /M transition because this domain (unlike the kinase domain) shares only 48% identity with that of X-PAK2 and is therefore unlikely to be able to compete with X-PAK2-Nter partners in the oocyte. Indeed, we observed in the course of this study that microinjection of X-PAK2-Nter domain in stage 6 oocytes inactivated the endogenous X-PAK2 kinase (data not shown).
In our previous report (8), we demonstrated that X-PAK1-Cter K/R facilitates oocyte maturation and hypothesized that the kinase domain could itself be regulated, as it contains a putative G␤ binding site (37) . This is also true for X-PAK2 (Fig.  3) , and at the moment we cannot rule out the possibility that other regulatory partners could be involved in endogenous X-PAK2 regulation, in addition to the Cdc42 GTPases as we have demonstrated in this study.
How Could Cdc42 and PAK Act as a Control Switch during Maturation?-This is still, of course, a matter of speculation. GTPases form a large family of small proteins that all share the ability to switch between an active GTP-bound and an inactive GDP-bound form. Nucleotide binding is a tightly regulated process, upon which the capability of the GTPase to activate downstream effectors depends. One of the best characterized members of this family is Ras. Oncogenic forms of Ha-Ras (Ha-Ras V12) were shown to induce GVBD in Xenopus (38) ; however, this Ras-dependent pathway is used exclusively in insulin mediated maturation and not in the physiological progesteronedependent process (for review, see Ref. 39) . Moreover, to date, Ha-Ras has not been identified in the Xenopus oocyte. Recently, using lethal toxin, a glucosyl transferase that inactivates a large number of small G proteins, Rime et al. (40) demonstrated that glucosylation of small GTPases spontaneously induces Xenopus oocyte maturation. In contrast, using toxin B, which inhibits more specifically Rho, Rac, and Cdc42 GTPase members, Rime et al. (40) no longer observed spontaneous maturation, only major cytoplasmic rearrangements. The authors conclude that the maturation pathway in oocytes must involve the inhibition of endogenous Ras or Rap members. We show in this report that microinjection of ectopic GTP-bound Cdc42, in order to constitutively activate the pathway used by endogenous X-PAK2, results in a complete block of progesterone-induced oocyte maturation. However, microinjection of GDP-bound Cdc42 (Cdc42N17), does not induce spontaneous maturation, although it reproducibly facilitates the process in progesterone-treated oocytes. This demonstrates that inhibition of Cdc42/X-PAK2 signaling pathway is absolutely required but is not sufficient for maturation to proceed. Crosstalk between signaling pathways used by GTPases from 
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different families are well described in the literature (41) (42) (43) , and it is conceivable, in light of these results, that the Cdc42/ PAK pathway is part of the signaling directed by a Ras and/or Rap GTPase in the control of Xenopus oocyte maturation.
X-PAK2 Is Inhibited by MPF during Oocyte MaturationEndogenous Xenopus PAK2 is active in resting oocytes. Upon progesterone treatment, the oocytes reenter the cell cycle, and 4 -5 h after initiation of hormone signaling, activated cyclin B-p34cdc2 complexes induce GVBD. Concomitantly, MPF also targets and inactivates X-PAK2 by phosphorylation. We were unable to "freeze" this likely very transient interaction and therefore to demonstrate a physical binding of X-PAK2 with MPF, in ovo, at this time. Nevertheless the data we present in this study directly link, in the course of a physiological event (oocyte maturation), the control by a cyclin-Cdk complex of a p21-activated kinase (PAK), a family of proteins directly involved in cytoskeleton rearrangements.
Our results strengthen several other recent studies, which predict that GTPase/p21-activated kinases are likely to be involved with cyclin-Cdk complexes in perhaps multiple pathways that regulate not only cell cycle progression but also, and most importantly, the cell physical and morphological changes that are associated. Indeed, the activity of Cla4, a S. cerevisiae member of the PAK family, was recently shown to be regulated during the cell cycle. Unlike X-PAK2, Cla4 activity peaks upon phosphorylation, at mitosis and before cytokinesis (44) . Cla4 is also involved through a multiple protein complex including Cdc42 in the pathway used by Clb2-Cdc28 kinase to control bud growth during mitosis . Ste20 phosphorylation mediated by Cln2-Cdc28 was also shown to occur in a cell cycle-dependent manner (46) , but interestingly, phosphorylation does not affect Ste20 kinase activity but rather induces its complete redistribution from a diffuse state in the cell to its concentration to the polarized region of the bud.
Finally, it was recently demonstrated that hPak1 is inactivated by p35/Cdk5 kinase (47) . Although the authors did not present a physiological event in which such a process may occur, they clearly show that p35 can bind Rac1 and that the active p35/Cdk5 complex can inhibit in a dose-dependent manner the active Rac1-Pak1 complex by hyperphosphorylating PAK1. Immunostaining experiments indicate that such regulation is likely to occur in highly dynamic areas of the neuron.
Because Xenopus Cdc42 has not yet been isolated and commercial antibodies against Cdc42 do not satisfactorily recognize endogenous Xenopus Cdc42, we were not able to address the question of whether inactivation of X-PAK2 by MPF is dependent upon the binding of the GTPase. However, and in contrast with the results of Nikolic et al. (47) , although we observed phosphorylation of X-PAK2 by MPF, we never observed hyperphosphorylated forms under these conditions. Nevertheless, we were able to induce a dramatic shift of X-PAK2 kinase by addition of recombinant GTP-bound Cdc42 (Cdc42V12) in meiotic metaphase II egg extracts (CSF extracts). These shifts were always correlated with a very strong activity of X-PAK2. We believe that hyperphosphorylated forms of X-PAK2 do not reflect a physiological event occurring during maturation because they are visualized either after several hours of incubation of the egg extract with a set amount of Cdc42V12 or after short incubation but with increased amounts of Cdc42V12. Moreover X-PAK2 hyperphosphorylation not only is observed in CSF-arrested egg extracts but can be reproduced in interphase egg extracts devoid of MPF activity, which further indicate that involvement of cyclin B-p34cdc2 in this mechanism is unlikely. 2 An intriguing question raised by the above mentioned studies is why cyclin/Cdk complexes are required to modulate PAK/ GTPase activity when GDP dissociation inhibitor, GTPaseactivating protein, and guanine nucleotide exchange factor already tightly regulate the GTP/GDP-bound state of GTPases and as a consequence the activation of their effectors. A number of explanations can be proposed. Such regulation could be spatially limited in the cell and restricted to subdomains, such as the growing tip of an axon, where a specific event occurs. Another possibility could be that there exists another checkpoint, which could couple cell cycle progression to cytoskeleton rearrangements. It was demonstrated, while this work was in progress, that a novel effector domain of Cdc42 is involved in triggering the apical/isotropic growth switch and G 2 /M transition in yeast (48) . In the model that we describe in this paper, it is possible to envision that inactivation of Cdc42/PAK activity is required for assembly of the microtubule array and nucleus migration, and indeed, Cdc42 was previously shown to be involved in nuclear migration, in four-cell mouse embryos (49) . In our model, such an event should start only once germinal vesicle breakdown has occurred; otherwise, germinal vesicle migration may occur in the absence of a spindle. It is interesting in this regard to note that Rime et al. (40) observed strong cytoskeleton rearrangements upon treatment of the oocytes with Toxin B. We observed ourselves that microinjection of Cdc42N17, an inactive GDP-bound mutant, although it does not induce GVBD by itself in the absence of hormonal treatment, frequently induces migration of the intact germinal vesicle to the cortex (as verified by fixing and dissection of the oocyte), which induced ballooning of the oocyte at the animal cortex (data not shown).
In conclusion, our results, taken together, suggest that X-PAK2 is involved in maturation control at two different levels. The first is exerted by the X-PAK2/Cdc42 pathway over an upstream element of the MPF amplification loop and possibly also on the maintenance of specific cytoskeleton structures in the oocyte. Once some MPF activity has been formed by an as yet unknown pathway, inactivation of X-PAK2 by newly formed MPF occurs. One can speculate that this inactivation could be a signal for spindle formation and migration to the animal cortex. We propose such a model in Fig. 8 .
As such, it will certainly be of interest to study the precise subcellular localization of PAK2 during the maturation process, especially when germinal vesicle breakdown occurs, in conjunction with the microtubule and the actin cytoskeleton rearrangements. Another point of interest will be to investigate the effects, once GVBD has occurred, of the overexpression of the small recombinant GTPase Cdc42 or of recombinant active PAK2 on the oocyte cytoskeleton, the TMA assembly, the transport of the meiotic spindle, and its anchor to the animal cortex.
